GlassScriptPhysician profile
Mitul Dadhania
NPI 1063778454
$1,654.16
in general payments reported to CMS, 2019-2025
23 companies · $40.22 in 2025
The $40.22 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $133 · 2021: $577 · 2022: $191 · 2023: $117 · 2024: $110 · 2025: $40.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.33 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.79 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $270.66 | 2019-2023 | Spravato |
| Biohaven Pharmaceuticals, INC. | $235.61 | 2021 | |
| Allergan, INC. | $144.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $110.37 | 2024 | Airsupra |
| Novo Nordisk INC | $109.01 | 2019-2022 | |
| Amgen INC. | $59.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.51 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.84 | 2023 | |
| Esperion Therapeutics, INC. | $35.47 | 2021-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $26.39 | 2019-2022 | |
| Shire North American Group INC | $26.33 | 2019 | |
| Astellas Pharma US INC | $25.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.36 | 2019 | |
| Amarin Pharma, INC. | $18.27 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $16.69 | 2019 | |
| Dexcom, INC. | $15.43 | 2022 | |
| Ucb, INC. | $15.36 | 2019 | |
| Merck Sharp & Dohme LLC | $15.02 | 2020 | |
| Lilly USA, LLC | $14.22 | 2022 | |
| Gilead Sciences, INC. | $12.50 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.46 | 2019 | |
| Lundbeck LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Dadhania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.